Latest Breaking News On - Jana alfheim - Page 1 : comparemela.com

Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes

Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Bruxelles capitaleMichel goldman universitJana alfheimCourtney turianoLinear energy transferChief executive officerField chief editor prof michel goldmanStern investor relations

Oncoinvent AS: Oncoinvent Announces Two Publications in Special Edition of Frontiers in Medicine Focused on Alpha Radioisotopes

Publications highlight the safety and tolerability of Radspherin for patients and those externally exposed to radiation, all dose levels were well tolerated with dose level toxicity (DLT) not reached.

Bruxelles capitaleMichel goldman universitCourtney turianoJana alfheimLinear energy transferChief executive officerField chief editor prof michel goldmanStern investor relations

Oncoinvent Initiates Radspherin® Phase 2A Trial

Press release content from Business Wire. The AP news staff was not involved in its creation.

Jana alfheimCourtney turianoUppsala university hospital in swedenLinear energy transferRadium hospitalOslo norwayUppsala university hospitalUppsala swedenChief executive officerChief executiveStern investorBusiness wireClinical trials

Oncoinvent AS: Data From the Ongoing Radspherin RAD-18-002 Phase 1 Trial in Colorectal Cancer Patients to Be Presented at the 2022 ASCO Annual Meeting

All dose levels of Radspherin were well tolerated with a maximum dose level toxicity not reached in the RAD-18-002 study. Radspherin is currently being evaluated in two ongoing Phase 1 trials for

United statesJana alfheimCourtney turianoSteing larsenKostenloser wertpapierhandelStein gunnar larsenAmerican society of clinical oncologyLinear energy transferUppsala university hospitalClinical oncologyAnnual meetingPrinciple investigator stein gunnar larsenCancer colorectalChief executive officerPresentation titleGastrointestinal cancer colorectal

Oncoinvent to Present at Guggenheim Radiopharmaceuticals Day

Oncoinvent AS, a clinical stage company advancing a pipeline of radiopharmaceutical products across a variety of solid cancers, today announced that members of management will present at the Guggenheim

New yorkUnited statesJana alfheimCourtney turianoKostenloser wertpapierhandelCharles zhuFusion pharmaceuticalsLinear energy transferGuggenheim securitiesGuggenheim radiopharmaceuticals dayPoint biopharmaAktis oncologyCurie therapeuticsVice president guggenheim securitiesChief executive officerStern investor relations